Magazine Article | March 1, 2022

A Cover Feature Four Years In The Making

Source: Life Science Leader

By Dan Schell, Chief Editor, Clinical Leader

I’m not sure what prompted the response from Rachel Haurwitz. It was, after all, a simple “thank you” that I had sent her via LinkedIn back in November 2017 for contributing some comments to our 2018 outlook issue. As CEO and president of one of the hottest CRISPR-based companies at the time, Caribou Biosciences, Haurwitz, I was sure, was inundated with LinkedIn connection requests and every other form of communication that clogs a top executive’s inbox. So when I almost immediately got a response, I was shocked.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader